相关实验视频
Updated: Sep 19, 2025

06:38
Screening and Isolation of C-Glycoside-Cleaving Intestinal Bacteria
Published on: February 28, 2025
457
新兴的肠道微生物糖化物酸酶抑制剂
Mark E Kowalewski1, Matthew R Redinbo1,2,3
1Department of Biochemistry and Biophysics, University of North Carolina Chapel Hill North Carolina USA redinbo@unc.edu.
RSC chemical biology
|June 19, 2025
概括
肠道微生物糖化物酸酶 (GHs) 通过代谢食和药物化合物,影响健康. 针对这些酶的抑制剂为与肠道微生物群功能相关的各种疾病提供了新的治疗策略.
科学领域:
- 微生物学和生物化学
- 肠道微生物组研究研究
- 酶抑制剂开发 酶抑制剂开发
背景情况:
- 人的肠道微生物群通过分子新陈代谢在宿主健康和疾病中发挥着至关重要的作用.
- 葡萄糖化酶 (GHs) 是一种关键的微生物酶,可以从饮食,宿主和异生菌中降解葡萄糖.
- 现有的GH抑制剂用于治疗溶酶体储存疾病,病毒感染和II型糖尿病.
研究的目的:
- 审查新兴类型的糖化酶 (GH) 抑制剂.
- 探索GH抑制剂在研究肠道微生物酶中的应用.
- 突出针对肠道微生物GHs治疗干预的潜力.
主要方法:
- 关于甘酸酶抑制剂及其应用的当前文献的综述.
- 针对宿主衍生型甘氨酸,食和异生物分子的GH抑制剂的分析.
- 检查基于活动的探针来识别特定的肠道微生物GHs.
主要成果:
- 越来越多的GH抑制剂类别是研究肠道微生物GHs的有效工具.
- GH抑制剂可以准宿主衍生的甘氨酸和异生菌的微生物降解.
- 基于活动的探测器有助于确定影响宿主结果的特定微生物蛋白质.
结论:
- 了解肠道微生物GH功能对于阐明宿主生理学和疾病至关重要.
- 用抑制剂向肠道微生物GHs提供了有前途的治疗途径.
- 这种方法通过调节非宿主因素,为急性和慢性疾病提供了潜在的干预措施.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
276
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
276
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
207
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
207
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
325
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
325
Glucagon-like Receptor Agonists
435
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
435
Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
335
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
335

